Purpose: To retrospectively evaluate biochemical control and toxicity in patients who underwent 125I seed brachytherapy (BT) for intermediate-risk prostate cancer (PCa).
Materials And Methods: Between January 2004-December 2014, 395 patients with intermediate-risk PCa underwent 125I BT. Of these, 117 underwent preoperative planning (PP; 145 Gy) and 278 real-time intraoperative preplanning (IoP; 160 Gy). All patients were followed for ≥ 6 months (> 5 years in 48% of patients and > 7 years in 13%). Median follow-up was 59 months.
Results: Biochemical relapse-free survival (BRFS) rates at 5 and 8 years were, respectively, 91.7% and 82.1%. By treatment group, the corresponding BRFS rates were 93.5% and 90% for IoP and 89% and 76.8% for PP. The maximum dose to the urethra remained unchanged (217 Gy) despite the dose escalation (from 145 to 160 Gy), without any significant increase in treatment-related toxicity (p = 0.13). Overall toxicity outcomes in the series were excellent, with only 3 cases (0.76%) of grade 3 genitourinary toxicity.
Conclusion: The real-time intraoperative planning technique at 160 Gy yields better biochemical controls than the preoperative planning technique at 145 Gy. Dose escalation did not increase urinary toxicity. The excellent results obtained with the IoP BT technique support its use as the first treatment option in this patient population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256233 | PMC |
| http://dx.doi.org/10.1016/j.rpor.2020.04.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care.
Brachytherapy
January 2025
BC Cancer Kelowna, Kelowna, British Columbia.
Purpose: High dose rate (HDR) brachytherapy is increasingly adopted for dose escalation in prostate cancer treatment. We report the clinical efficacy and toxicity of HDR prostate brachytherapy combined with external beam radiotherapy (EBRT) and evaluate the predictability of the biochemical definition of cure of 4-year PSA ≤0.2 ng/mL for failure free survival (FFS).
View Article and Find Full Text PDFUltra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Article Synopsis
- The study retrospectively evaluated the effectiveness of ultra-low dose rate brachytherapy (uLDR-BT) in 39 patients with unfavorable intermediate risk prostate cancer, despite current guidelines recommending against it due to insufficient evidence.
- Results showed a promising median follow-up of about 56 months, with an 87.02% biochemical failure-free survival rate, indicating uLDR-BT could be a viable treatment option.
- No significant differences in outcomes were observed based on additional risk factors or treatment methods, suggesting that uLDR-BT's effectiveness is consistent across different patient profiles in the intermediate risk category.
Comparing the efficacy of tadalafil and tamsulosin for managing erectile dysfunction and lower urinary tract symptoms in prostate brachytherapy patients: a prospective study.
Prostate Int
December 2024
Department of Urology, Keio University, School of Medicine, Tokyo, Japan.
Introduction: Adverse events, such as erectile dysfunction (ED) and lower urinary tract symptoms (LUTS), are significant concerns in prostate cancer (PCa) patients treated with Iodine 125 (I-125) low-dose rate (LDR) prostate brachytherapy (PB). Alpha antagonists and phosphodiesterase-5 inhibitors are used to manage these events. The present study compared the efficacy of low-dose tadalafil with that of tamsulosin for concomitant ED and LUTS in PCa patients treated with I-125 LDR PB.
View Article and Find Full Text PDFProstate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data.
Am J Clin Oncol
January 2025
Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Objective: We sought to compare our results of patients treated with Cs-131 prostate brachytherapy (PB) as monotherapy to recently published results of patients treated with stereotactic body radiotherapy.
Methods: We analyzed data from patients treated at our institution with Cs-131 PB as monotherapy who had at least 5 years of follow-up and who prospectively completed expanded prostate cancer index composite questionnaires at baseline, 1 year, 2 years, and 5 years. We compared our data with the recently published data from radiation therapy oncology group (RTOG) 0938 and PACE-B (NCT01584258).
Ladies project: large database in endometrial cancers for a personalized treatment.
Radiol Med
December 2024
Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy.
Purpose: To compare Italian use with current international guidelines and to evaluate oncological outcomes and toxicity patterns of adjuvant radiation therapy (RT) for endometrial cancer (EC) in Italian women.
Materials And Methods: To conduct a retrospective multicentre Italian study a large database was set up. Inclusion criteria were: accrual between 2010 and 2020, treatment with surgery, post-operative external beam RT (EBRT) and/or interventional radiotherapy (IRT) associated or not with adjuvant chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!